A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) - Trial NCT05279846
Access comprehensive clinical trial information for NCT05279846 through Pure Global AI's free database. This Phase 3 trial is sponsored by Moberg Pharma AB and is currently Recruiting. The study focuses on Onychomycosis. Target enrollment is 350 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Moberg Pharma AB
Timeline & Enrollment
Phase 3
May 09, 2022
Mar 01, 2024
Primary Outcome
Proportion of subjects with complete cure of the target toenail,Incidence of adverse events (Safety)
Summary
This is a Phase 3 multicenter, double blind study to evaluate the safety and efficacy of
 vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05279846
Non-Device Trial